Tiumbio Showcases Promising Clinical Results for Novel Cancer Drug at SITC 2025 Tiumbio Co., Ltd. revealed exciting interim Phase II clinical results for Tosposertib at SITC 2025, showcasing impressive response rates.

Tiumbio Showcases Promising Clinical Results for Novel Cancer Drug at SITC 2025 #South_Korea #Seongnam #TiumBio #Tosposertib #SITC2025

TiumBio and Daewon Pharmaceutical Achieve Success with Merigolix in Phase 2 Trial for Uterine Fibroids TiumBio and Daewon Pharmaceutical have successfully completed Phase 2 trials for Merigolix, showing significant reduction in heavy menstrual bleeding for uterine fibroids.

TiumBio and Daewon Pharmaceutical Achieve Success with Merigolix in Phase 2 Trial for Uterine Fibroids #South_Korea #Seongnam #Merigolix #TiumBio #Daewon

TiumBio and Hansoh Pharma: A Breakthrough in ART Development for Merigolix TiumBio announces that its partner, Hansoh Pharma, expands the indications for Merigolix, paving the way for innovative ART treatments to enhance fertility outcomes.

TiumBio and Hansoh Pharma: A Breakthrough in ART Development for Merigolix #South_Korea #Seongnam #Hansoh_Pharma #Merigolix #TiumBio